Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0C1EO
|
||||
| Former ID |
DIB009303
|
||||
| Drug Name |
Melanoma vaccine
|
||||
| Synonyms |
Melanoma vaccine (ALVAC); Melanoma vaccine (ALVAC), sanofi pasteur; Melanoma vaccine (gp100/MAGE-1/MAGE-3/MART-1/NY-ESO-1, ALVAC), sanofi pasteur
|
||||
| Drug Type |
Vaccine
|
||||
| Indication | Melanoma [ICD9: 172; ICD10:C43] | Discontinued in Phase 2 | [1] | ||
| Company |
Sanofi Pasteur
|
||||
| Target and Pathway | |||||
| Target(s) | Melanoma associated antigen 1 | Target Info | [2] | ||
| NY-ESO-1 | Target Info | [2] | |||
| Melanocytes lineage-specific antigen GP100 | Target Info | [2] | |||
| Melanoma-associated antigen 3 | Target Info | [2] | |||
| MART-1 melanoma antigen | Target Info | [2] | |||
| WikiPathways | Notch Signaling Pathway | ||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014153) | ||||
| REF 2 | Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.